Actuate Therapeutics
ACTU
61 hedge funds and large institutions have $38M invested in Actuate Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 10
36% more funds holding
Funds holding: 45 → 61 (+16)
2.04% more ownership
Funds ownership: 56.4% → 58.45% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
53% less capital invested
Capital invested by funds: $80.2M → $38M (-$42.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$1.76M |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$469K |
| 3 |
PVM
Palogic Value Management
Dallas,
Texas
|
+$414K |
| 4 |
ADEF
ABS Direct Equity Fund
Stamford,
Connecticut
|
+$180K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$102K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$59.1K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$54K |
| 5 |
Barclays
London,
United Kingdom
|
-$52.9K |
ACTU Hedge Fund Activity: Q1 2026 in Review
61 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Actuate Therapeutics (ACTU) for Q1 2026, worth a combined $38M — down 53% from $80.2M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ACTU positions and 4 closed out — a net gain of 18 holders — while 20 added to existing stakes and 10 trimmed.
The largest buyer was Voss Capital, adding an estimated $1.76M. The largest seller was Jane Street, exiting entirely with an estimated $102K sold.
- 61 institutional investors held Actuate Therapeutics (ACTU) as of Q1 2026, up from 45 in Q4 2025.
- Funds reported $38M of Actuate Therapeutics stock for Q1 2026, down 53% quarter-over-quarter.
- 22 funds opened new Actuate Therapeutics positions in Q1 2026 and 4 closed out, a net change of +18 holders.
- The largest Actuate Therapeutics buyer in Q1 2026 was Voss Capital, an estimated $1.76M added.
- The largest Actuate Therapeutics seller in Q1 2026 was Jane Street, an estimated $102K sold.
Based on aggregated 13F filings for Q1 2026.